Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

201 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Tumour location and efficacy of first-line EGFR inhibitors in KRAS/RAS wild-type metastatic colorectal cancer: retrospective analyses of two phase II randomised Spanish TTD trials.
Benavides M, Díaz-Rubio E, Carrato A, Abad A, Guillén C, Garcia-Alfonso P, Gil S, Cano MT, Safont MJ, Gravalos C, Manzano JL, Sánchez A, Alcaide J, López R, Massutí B, Sastre J, Martínez E, Escudero P, Méndez M, Aranda E. Benavides M, et al. Among authors: escudero p. ESMO Open. 2019 Dec 1;4(6):e000599. doi: 10.1136/esmoopen-2019-000599. eCollection 2019. ESMO Open. 2019. PMID: 31803504 Free PMC article. Clinical Trial.
First-line panitumumab plus FOLFOX4 or FOLFIRI in colorectal cancer with multiple or unresectable liver metastases: A randomised, phase II trial (PLANET-TTD).
Carrato A, Abad A, Massuti B, Grávalos C, Escudero P, Longo-Muñoz F, Manzano JL, Gómez A, Safont MJ, Gallego J, García-Paredes B, Pericay C, Dueñas R, Rivera F, Losa F, Valladares-Ayerbes M, González E, Aranda E; Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD). Carrato A, et al. Among authors: escudero p. Eur J Cancer. 2017 Aug;81:191-202. doi: 10.1016/j.ejca.2017.04.024. Epub 2017 Jun 19. Eur J Cancer. 2017. PMID: 28633089 Free article. Clinical Trial.
First-Line Biological Agents Plus Chemotherapy in Older Patients with Metastatic Colorectal Cancer: A Retrospective Pooled Analysis.
García-Alfonso P, Díaz-Rubio E, Abad A, Carrato A, Massutí B, Ortiz-Morales MJ, Manzano Mozo JL, Muñoz A, Durán G, Sastre J, Safont MJ, Ferreiro R, Rivera F, González E, Valladares-Ayerbes M, Grávalos C, Alonso-Orduña V, Viéitez JM, Yubero A, Aranda E; Spanish Cooperative Group for the Treatment of Digestive Tumors (TTD). García-Alfonso P, et al. Drugs Aging. 2021 Mar;38(3):219-231. doi: 10.1007/s40266-021-00834-w. Epub 2021 Feb 22. Drugs Aging. 2021. PMID: 33615402 Free PMC article.
Influence of BRAF and PIK3CA mutations on the efficacy of FOLFIRI plus bevacizumab or cetuximab as first-line therapy in patients with RAS wild-type metastatic colorectal carcinoma and <3 baseline circulating tumour cells: the randomised phase II VISNÚ-2 study.
Sastre J, García-Alfonso P, Viéitez JM, Cano MT, Rivera F, Reina-Zoilo JJ, Salud-Salvia A, Quintero G, Robles-Díaz L, Safont MJ, La Casta A, Gil S, Polo E, Asensio-Martínez E, García-Paredes B, López RL, Guillot M, Valladares-Ayerbes M, Aranda E, Díaz-Rubio E; Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD). Sastre J, et al. ESMO Open. 2021 Apr;6(2):100062. doi: 10.1016/j.esmoop.2021.100062. Epub 2021 Mar 10. ESMO Open. 2021. PMID: 33711671 Free PMC article. Clinical Trial.
First-line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: the phase III MACRO TTD study.
Díaz-Rubio E, Gómez-España A, Massutí B, Sastre J, Abad A, Valladares M, Rivera F, Safont MJ, Martínez de Prado P, Gallén M, González E, Marcuello E, Benavides M, Fernández-Martos C, Losa F, Escudero P, Arrivi A, Cervantes A, Dueñas R, López-Ladrón A, Lacasta A, Llanos M, Tabernero JM, Antón A, Aranda E; Spanish Cooperative Group for the Treatment of Digestive Tumors. Díaz-Rubio E, et al. Among authors: escudero p. Oncologist. 2012;17(1):15-25. doi: 10.1634/theoncologist.2011-0249. Epub 2012 Jan 10. Oncologist. 2012. PMID: 22234633 Free PMC article. Clinical Trial.
A randomized phase II study of capecitabine-based chemoradiation with or without bevacizumab in resectable locally advanced rectal cancer: clinical and biological features.
Salazar R, Capdevila J, Laquente B, Manzano JL, Pericay C, Villacampa MM, López C, Losa F, Safont MJ, Gómez A, Alonso V, Escudero P, Gallego J, Sastre J, Grávalos C, Biondo S, Palacios A, Aranda E. Salazar R, et al. Among authors: escudero p. BMC Cancer. 2015 Feb 26;15:60. doi: 10.1186/s12885-015-1053-z. BMC Cancer. 2015. PMID: 25886378 Free PMC article. Clinical Trial.
Is aflibercept an optimal treatment for wt RAS mCRC patients after progression to first line containing anti-EGFR?
Vera R, Mata E, González E, Juez I, Alonso V, Iranzo P, Martínez NP, López C, Cabrera JM, Safont MJ, Ruiz-Casado A, Salgado M, González B, Escudero P, Rivera F, Pericay C. Vera R, et al. Among authors: escudero p. Int J Colorectal Dis. 2020 Apr;35(4):739-746. doi: 10.1007/s00384-020-03509-x. Epub 2020 Feb 15. Int J Colorectal Dis. 2020. PMID: 32062727
Phase II randomized trial of capecitabine with bevacizumab and external beam radiation therapy as preoperative treatment for patients with resectable locally advanced rectal adenocarcinoma: long term results.
Salazar R, Capdevila J, Manzano JL, Pericay C, Martínez-Villacampa M, López C, Losa F, Safont MJ, Gómez-España A, Alonso-Orduña V, Escudero P, Gallego J, García-Paredes B, Palacios A, Biondo S, Grávalos C, Aranda E; Spanish Cooperative Group for the Treatment of Digestive Tumors (TTD). Salazar R, et al. Among authors: escudero p. BMC Cancer. 2020 Nov 27;20(1):1164. doi: 10.1186/s12885-020-07661-z. BMC Cancer. 2020. PMID: 33246428 Free PMC article. Clinical Trial.
Role of Kras status in patients with metastatic colorectal cancer receiving first-line chemotherapy plus bevacizumab: a TTD group cooperative study.
Díaz-Rubio E, Gómez-España A, Massutí B, Sastre J, Reboredo M, Manzano JL, Rivera F, Safont MJ, Montagut C, González E, Benavides M, Marcuello E, Cervantes A, Martínez de Prado P, Fernández-Martos C, Arrivi A, Bando I, Aranda E; Spanish Cooperative Group for the Treatment of Digestive Tumors (TTD). Díaz-Rubio E, et al. PLoS One. 2012;7(10):e47345. doi: 10.1371/journal.pone.0047345. Epub 2012 Oct 12. PLoS One. 2012. PMID: 23174912 Free PMC article. Clinical Trial.
Panitumumab and irinotecan every 3 weeks is an active and convenient regimen for second-line treatment of patients with wild-type K-RAS metastatic colorectal cancer.
Carrato A, Gómez A, Escudero P, Chaves M, Rivera F, Marcuello E, González E, Grávalos C, Constenla M, Manzano JL, Losa F, Maurel J, Dueñas R, Massuti B, Gallego J, Aparicio J, Antón A, Aranda E. Carrato A, et al. Among authors: escudero p. Clin Transl Oncol. 2013 Sep;15(9):705-11. doi: 10.1007/s12094-012-0993-x. Epub 2013 Jan 29. Clin Transl Oncol. 2013. PMID: 23359181 Clinical Trial.
201 results